<DOC>
	<DOCNO>NCT02485509</DOCNO>
	<brief_summary>A combined Phase Ib IIa randomize , placebo-controlled , double-blind study VM-1500 healthy subject patient HIV-1 infection antiretroviral therapy naïve .</brief_summary>
	<brief_title>Study Safety Pharmacokinetics Healthy Volunteers Safety , Tolerability Antiviral Activity VM-1500 Patients With Human Immunodeficiency Virus-1 Infection</brief_title>
	<detailed_description>The study split two part : Part I : A randomized , placebo-controlled , single dose , double-blind study healthy volunteer 20 mg follow 40 mg DSMB approval . Healthy group : one dose 1 PK day 12 health volunteer ( total ) : 6 subject randomize ( 4:2 ) VM-1500 20 mg placebo . After DSMB approval , 6 subject randomize ( 4:2 ) VM-1500 40 mg placebo Part II : A randomized , placebo-controlled , multiple dose , double-blind study 7 day patient HIV infection antiretroviral therapy-naïve . After positive DMSB review dose escalate 20 mg 40 mg daily . Patient group : 2 PK day ( in-house ) day 1 day 7 16 patient ( total ) : 8 subject randomize ( 7:1 ) VM-1500 20 mg placebo daily 7 day . After DSMB approval , 8 subject randomize ( 7:1 ) VM-1500 40 mg placebo daily 7 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Healthy Subjects : 1 . Male age 1840 year 2 . Has determine healthy physical examination , assessment drug abuse , medical history vital sign 3 . Has normal result follow screening test : complete blood count , blood urea nitrogen , serum creatinine , fast blood sugar , total bilirubin , aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase urinalysis . 4 . Negative result hepatitis B , hepatitis C HIV antibodies 5 . Willing participate sign informed consent form Inclusion Criteria Patients : 6 . Males female age 18 65 year 7 . HIV1 infection , document rapid HIV test license ELISA test kit confirm Western blot time prior study entry 8 . Antiretroviral therapy naïve . Exclusion Criteria Healthy Subjects : 1 . Hepatic kidney disorder disease disorder may opinion Investigator interfere result study threaten health volunteer ; 2 . Drug intake ( include herbal drug ) last month ; 3 . Active alcohol and/or drug abuse , opinion site investigator , would interfere adherence study requirement ; 4 . Volunteers take investigational drug least 3 month prior start study ; 5 . Inability understand Protocol follow instruction ; Exclusion Criteria Patients : 1 . Currently active AIDS defining illness 2 . Exclusionary resistance mutation define evidence major NNRTI mutation accord current IAS list HIV1 Resistance Mutations Associated Drug Resistance genotype ; evidence significant NNRTI resistance phenotype perform time prior study entry . 3 . Patients expect need systemic antiviral therapy time participation study . 4 . Patients receive investigational drug HIV , HIV vaccine , immunomodulators , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry ; 5 . Acute chronic viral hepatitis ; 6 . History evidence renal disease . 7 . Abnormal hematological biochemical parameter within 30 day Entry ( Day 1 ) . 8 . Screening ECG QTc value 450 ms. 9 . Consumption / administration concomitant medication . 10 . Active alcohol and/or drug abuse , opinion site investigator , would interfere adherence study requirement . 11 . Positive result urine screen drug abuse Screening Day 1 12 . History immunologically mediate disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>